Shanghai Haohai Biological Technology (SHA:688366, HKG:6826) obtained medical device registration from China's medical products administrator for its multifocal aspheric intraocular lens product.
The product is intended for vision correction in aphakic eyes of cataract patients, according to a Wednesday filing with the Shanghai bourse.
The registration is valid until March 2031.
Shares of the ophthalmic products manufacturer rose 3% on the Shanghai bourse and 2% on the Hong Kong bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.